Abbott Laboratories (ABT)

85.48
0.53 0.62
NYSE : Health Technology
Prev Close 84.95
Open 85.00
Day Low/High 82.95 / 85.95
52 Wk Low/High 61.61 / 92.45
Volume 6.69M
Avg Volume 8.78M
Exchange NYSE
Shares Outstanding 1.76B
Market Cap 144.48B
EPS 2.10
P/E Ratio 39.77
Div & Yield 1.44 (1.60%)

Latest News

Good-Bye to March 2020, Retailmageddon, 32% Unemployment? Trading DocuSign

Good-Bye to March 2020, Retailmageddon, 32% Unemployment? Trading DocuSign

I don't think it would be too much of a stretch to imagine that too many investors, or citizens for that matter, will mind seeing March 2020 head on out of here.

Jim Cramer: Abbott's 5-Minute Covid-19 Test Is a Big Win, but the War Wages On

Jim Cramer: Abbott's 5-Minute Covid-19 Test Is a Big Win, but the War Wages On

Now we need the gowns and masks from China to help fight this battle on the front lines.

In a Post-Coronavirus World, Put This Lesser-Known Stock on Your List

In a Post-Coronavirus World, Put This Lesser-Known Stock on Your List

Things will be different after Covid-19 and one change will be in how people care about themselves.

Abbott Labs Passes Our Test

Abbott Labs Passes Our Test

As it gets the OK for a new rapid Covid-19 detecting device, Abbott Labs could be purchased here following our new technical strategy.

Q2 Earnings Expectations, 4 Key Economic Questions, Trading Abbott Labs

Q2 Earnings Expectations, 4 Key Economic Questions, Trading Abbott Labs

I do believe that having no economy is temporary. I also believe that what comes out on the other side will be smaller, far less global.

Navigating These Times, Putting Cash to Work, Oil Price War, Trump Stimulus Plan

Navigating These Times, Putting Cash to Work, Oil Price War, Trump Stimulus Plan

Markets appear stable. Do we trust it? Can we trust it? Of course not.

Jim Cramer: I Don't Know Where It Will Bottom, I Do Know What to Buy and Sell

Jim Cramer: I Don't Know Where It Will Bottom, I Do Know What to Buy and Sell

This is the time to high grade your portfolio, take some losses and move to better stocks.

In This Market, Where Do We Draw the Line?

In This Market, Where Do We Draw the Line?

Everyone seems concerned that non-technology stocks are as vulnerable as the industrials and energy stocks.

Market Direction and Trading Volume, Resilient Boeing, Trading Costco

Market Direction and Trading Volume, Resilient Boeing, Trading Costco

Boeing's new estimate for the FAA's signing off on returning the 737 MAX to commercial skies has been pushed out until summer, June or July? Is that really that bad? Perhaps... this is a positive.

Abbott Laboratories Could Climb to the $107 Area Next

Abbott Laboratories Could Climb to the $107 Area Next

Barring a negative surprise I would look for higher highs to be established in the days and weeks ahead.

The Week Ahead: Davos, Impeachment, PMI and 25 Key Earnings Reports to Watch

The Week Ahead: Davos, Impeachment, PMI and 25 Key Earnings Reports to Watch

Almost 200 companies are slated to report quarterly results, including 43 S&P 500 constituents.

3 Boomer-Inspired Drug Plays With Dividend Appeal

3 Boomer-Inspired Drug Plays With Dividend Appeal

Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.

A Fresh Look at Abbott Labs Still Shows a Long-Term Uptrend in Place

A Fresh Look at Abbott Labs Still Shows a Long-Term Uptrend in Place

Let's review the charts of ABT.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Abbott Labs Has Concocted a Way to Advance Further

Abbott Labs Has Concocted a Way to Advance Further

The medical device and health care company is set to resume its long advance, with our first price target at $92 and next at $100.

Markets Bet on Growth, 3 Month/10 Year Spread, Trading Nvidia: Market Recon

Markets Bet on Growth, 3 Month/10 Year Spread, Trading Nvidia: Market Recon

The Fed is doing this right. Let me repeat... the Fed is not screwing this up.

Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers

Jim Cramer: Watch for Stocks Reporting 'Not as Bad as Feared' Numbers

When you have an oversold market you've got a true coiled spring that can rally beyond where it might ordinary go on good news.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

U.S. Monetary Policy, Trading Lockheed, Netflix and United Rentals: Market Recon

U.S. Monetary Policy, Trading Lockheed, Netflix and United Rentals: Market Recon

Preventing the U.S. dollar from appreciating too aggressively while repairing credit conditions are 'job freaking one'.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Jim Cramer: These 7 True Laggards Have Caught Fire

Jim Cramer: These 7 True Laggards Have Caught Fire

These kinds of stocks are what goes up when there's so little left that hasn't moved that can still be worth buying.

Good News From China, Plus Netflix Earnings and Playing CSX: Market Recon

Good News From China, Plus Netflix Earnings and Playing CSX: Market Recon

China reported positive data, bolstering markets. Netflix had a beat on earnings, but faces fierce competition ahead. CSX is a thing of beauty.

Trading Notes for Select Stocks

Trading Notes for Select Stocks

Here's my take on a list of stocks I've been watching.

Shares of Abbott Laboratories Poised for Upside Breakout

Shares of Abbott Laboratories Poised for Upside Breakout

ABT is pointed up after trading in a choppy range since October.

An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon

An IBM Play and 2 Catalysts To Watch in Wednesday's Trading: Market Recon

Keeping an eye on the Senate shutdown vote and any trade discussion today, and watching key support levels on the SPX.

Jim Cramer: If We Get a China Deal, Then This Rally Is In Its Infancy

Jim Cramer: If We Get a China Deal, Then This Rally Is In Its Infancy

The kick will come from the Chinese capitulating because their economy is so weak.

New Favorites for 2019 from Last Year's Top Stock Pickers

New Favorites for 2019 from Last Year's Top Stock Pickers

Mike Cintolo and Jim Woods saw their top picks for 2018 rise 81% and 75%, respectively.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.